A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma

Inclusion Criteria: * Sign the ICF * ≥ 12 years old * Have a persistent asthma diagnosis, as per GINA classification,18 with symptoms for at least 6 months and clinically stable for at least 1 month with the ACQ-7 test (please see Appendix C) ≤ 3.0 * Current use of inhaled corticosteroid (up to 1000 µg of beclomethasone dipropionate) whether combined or not with long-term β2-adrenergics and relief medication (salbutamol or equivalent) * Initial FEV1 of at least 40% of the normal value expected * Blood cortisol evaluation within the normal limits. Exclusion Criteria: * Use of oral or parenteral corticosteroid within the last 3 previous months to the study * Hospitalization needed due to asthma within the last 3 previous months to the study * Active smokers, defined as the consumption of cigarettes, pipes, cigars or any other form of smoking in any amount within the last 3 months * Presence of severe co-morbidities, such as cardiovascular, renal, liver, neurological, neoplastic, hematological, infectious, dermatological, neurological or psychiatric disease or chronic respiratory disease other than asthma * Recent (\<6 months) or expected participation during this study in other clinical trials involving drugs of any nature or in studies consisting of any - Intolerance or allergy to any component of the drugs evaluated in the study * Pregnant or lactating women * Chronic use of routine β-blockers, orally or intravenously, including ophthalmic solutions.